Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Venous thromboembolism prophylaxis after bariatric surgery (n=1276). Intervention: Enoxaparin vs. Enoxaparin 60 mg. Primary outcome: Achievement of target prophylactic anti-factor Xa levels (RR 0.96, 95% CI 0.85-1.09, p=0.5265).

Q: What does this research mean for the field?

Higher-dose enoxaparin (60 mg) increases anti-factor Xa levels compared to standard-dose (40 mg) in bariatric surgery patients, but does not significantly improve target prophylactic anti-Xa achievement or reduce venous thromboembolism, bleeding, or mortality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mahmoud Albashier; Ibrahim Moqbel; Ahmad Omar Saleh; Rawan Kamal Mohammed; Mohammad Mahadin; Mohamed Hany Ezz; Mahmoud Omar Dakhly; Yahya A. Mahmoud; Hosam Elghadban

doi:10.1007/s11695-026-08765-4

June 10, 2026Obesity SurgeryOpen Access

Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes

View Full Paper

Ask AI

Bookmark

Share

Key result

Enoxaparin 40 mg did not significantly differ from 60 mg in achieving target prophylactic anti-factor Xa levels (RR 0.96) or reducing venous thromboembolism in bariatric surgery patients.

Figures

Why the study?

Standard prophylactic dosing of enoxaparin may be inadequate after bariatric surgery due to obesity-related hypercoagulability and pharmacokinetic changes, but the comparative efficacy and safety of standard-dose versus higher-dose enoxaparin remain unclear.

Does enoxaparin 60 mg improve the achievement of prophylactic anti-factor Xa levels and reduce venous thromboembolism compared to 40 mg in patients undergoing bariatric surgery?

Key Points

To evaluate the comparative pharmacologic efficacy and clinical safety of standard 40 mg versus higher 60 mg enoxaparin regimens for postoperative venous thromboembolism prophylaxis in bariatric surgery.
A systematic search across five databases through September 30, 2025, identified 10 randomized trials and cohort studies comprising 1,276 bariatric surgery patients (727 receiving 40 mg and 549 receiving 60 mg enoxaparin).
Eligible studies evaluated fixed-dose or BMI-tiered prophylactic regimens, tracking anti-factor Xa levels and clinical outcomes up to three months postoperatively using random-effects meta-analyses.
Overall achievement of target prophylactic anti-Xa levels did not differ between doses (RR 0.96; 95% CI 0.85–1.09; p=0.5265), though once-daily 40 mg was less likely to reach targets than once-daily 60 mg (RR 0.70; 95% CI 0.50–0.99; p=0.0464).
No significant differences occurred between groups for venous thromboembolism, deep vein thrombosis, pulmonary embolism, bleeding incidents, mortality, overall complications, operative duration, or transfusion requirements.

Study Design

Type

Meta-Analysis (n=1,276)

Structured PICO

Does enoxaparin 60 mg improve the achievement of prophylactic anti-factor Xa levels and reduce venous thromboembolism compared to 40 mg in patients undergoing bariatric surgery?

P

Population

1,276 patients undergoing bariatric surgery across 10 studies followed for up to 3 months to evaluate postoperative venous thromboembolism prophylaxis.

I

Intervention

Enoxaparin 60 mg administered once or twice daily (using fixed-dose or BMI-tiered dosing strategies) for postoperative venous thromboembolism prophylaxis

C

Comparator

Enoxaparin 40 mg administered once or twice daily (using fixed-dose or BMI-tiered dosing strategies) for postoperative venous thromboembolism prophylaxis

O

Outcome

Proportion of patients who achieved prophylactic anti-factor Xa concentrations within the range of 0.2-0.5 IU/mLsurrogate

Main Result

Relative Risk: 0.96 (95% CI 0.85–1.09)

p-value: p=0.5265

Higher prophylactic doses of enoxaparin (60 mg) alter anti-factor Xa levels but do not significantly improve target prophylactic attainment or reduce clinical venous thromboembolism compared to standard 40 mg dosing in bariatric surgery patients.

Limitations

High between-study heterogeneity
Inclusion of BMI-tiered studies introducing confounding
Variability in blood sample collection timing
Small sample sizes and low event rates for clinical outcomes
Major publication bias and small-study effects
Substantial statistical heterogeneity in anti-factor Xa level outcomes
Confounding as the primary source of bias among the included non-randomized studies

Implication

40 mg enoxaparin suffices for post-bariatric VTE prophylaxis; challenges routine higher dosing absent clinical outcome gains.

Abstract

Background Patients undergoing bariatric surgery face an elevated risk of venous thromboembolism (VTE), primarily due to obesity-related hypercoagulability and changes in the pharmacokinetics of anticoagulants. The standard prophylactic dosing of enoxaparin may not be adequate for this group, leading to the consideration of higher or BMI-adjusted dosing regimens. Nevertheless, the comparative efficacy and safety of standard-dose versus higher-dose enoxaparin in the context of bariatric surgery remain unclear. Methods A systematic review and meta-analysis were performed following the PRISMA 2020 guidelines. Searches were conducted in PubMed, Embase, Scopus, Web of Science, and the Cochrane Library from their inception through September 30, 2025. The review included randomized controlled trials and cohort studies comparing enoxaparin 40 mg with 60 mg for postoperative venous thromboembolism (VTE) prophylaxis in bariatric surgery. Studies utilizing fixed-dose or BMI-tiered dosing strategies were considered eligible. The primary outcome assessed was the achievement of prophylactic anti-factor Xa levels. Secondary outcomes comprised mean anti-factor Xa levels, sub- and supra-prophylactic anti-factor Xa levels, VTE occurrence, bleeding incidents, mortality rates, overall complications, operative duration, and transfusion requirements. Random-effects meta-analyses were conducted. Results Ten studies encompassing 1,276 patients (727 receiving 40 mg and 549 receiving 60 mg) were included. Enoxaparin 40 mg was associated with significantly lower mean anti-factor Xa levels compared with 60 mg (MD − 0.08 IU/mL; 95% CI − 0.13 to − 0.03). Patients receiving 40 mg had higher rates of sub-prophylactic anti-Xa levels (RR 1.35; 95% CI 1.03–1.77), whereas 60 mg was associated with increased supra-prophylactic levels (RR 0.25; 95% CI 0.09–0.70). Overall achievement of target prophylactic anti-Xa levels did not differ between doses, although once-daily 40 mg dosing was associated with reduced target attainment compared with once-daily 60 mg. No significant differences were observed in VTE, deep vein thrombosis, pulmonary embolism, bleeding, mortality, overall complications, operative duration, or transfusion requirements. Conclusions Although higher enoxaparin doses improved anti-factor Xa levels, this did not translate into reductions in venous thromboembolism, bleeding, or mortality, underscoring the disconnect between pharmacokinetic markers and clinical outcomes in bariatric surgery patients. Registration PROSPERO CRDXXXXXXXXXXX.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Albashier et al. (2026) conducted a meta-analysis in Venous thromboembolism prophylaxis after bariatric surgery (n=1,276). Enoxaparin vs. Enoxaparin 60 mg was evaluated on Achievement of target prophylactic anti-factor Xa levels (RR 0.96, 95% CI 0.85-1.09, p=0.5265). Enoxaparin 40 mg did not significantly differ from 60 mg in achieving target prophylactic anti-factor Xa levels (RR 0.96) or reducing venous thromboembolism in bariatric surgery patients.

synapsesocial.com/papers/6a2ba4778101cf8926f02d2c https://doi.org/10.1007/s11695-026-08765-4

View Full Paper

Ask AI

Bookmark

Share

Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Enoxaparin 40 mg Versus 60 mg for Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Systematic Review and Meta-Analysis of Pharmacologic and Clinical Outcomes

Figures

Key Points

Study Design

Structured PICO

Main Result

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Obesity Surgery

Keep reading

More related papers

More from Obesity Surgery